Omeros Corporation reported financial results for the second quarter ended June 30, 2026. YARTEMLEA gross revenues increased 190% to $32.2 million, with net revenue of $28.5 million. GAAP net income was $13.2 million ($0.18 per share), excluding an $11.5 million non-cash gain from convertible note derivatives; adjusted net income was $1.8 million ($0.02 per share). The company held $132.0 million in cash and short-term investments. In July, Omeros repurchased $30.5 million of its 2029 Notes for $60.2 million, reducing outstanding principal to approximately $40.3 million and eliminating $8.6 million in future interest payments. Additionally, the company retired 0.5 million shares of common stock during the quarter at an average cost of $11.70 per share. Omeros is a biotechnology company that discovers and develops therapeutics for complement-mediated diseases, cancers, and addictive disorders.
